In addition, DNMT1i azacytidine represses the growth of IDH1 mutant gliomas in vivo, accompanied by hypomethylation and marked cellular differentiation, with no tumor recurrence observed up to 7 weeks after drug withdrawal [76]. The gene discussed is IDH1; the disease is glioma.